CTLA4 and neoplasm: Of interest, it was confirmed that tumours belonging to the IIH-FH subgroup expressed the most immunomodulatory genes, such as TIM3, IDO-1, LAG3, TIGIT and OX40, making them potential candidates for classic CPI (anti PD-L1, PD1, CTLA4) or novel immunotherapy combinations such as anti-LAG3 and anti-TIM3 bispecific antibodies which could overcome primary or secondary resistance [45].